Studied in the lab, clinically validated in humans: The science behind Basis.
Elysium’s first double-blind, randomized, placebo-controlled clinical trial, published in November 2017 in the peer-reviewed journal Nature Partner Journals: Aging and Mechanisms of Disease, demonstrated that Basis is clinically proven to increase NAD+ levels by an average of 40 percent from baseline in adults taking the recommended daily dose.
We are committed to conducting rigorous scientific research and sharing it with our customers, which is why we publish our work in open access, peer-reviewed journals. Read the full results of the study in Nature Partner Journals: Aging and Mechanisms of Disease.
|Location||Three sites: London, Ontario (Canada), Orlando, Florida, and Irvine, California.|
|Participants||120 healthy adults between the ages of 60 and 80 years|
|Protocol||Double-blind, placebo-controlled, randomized—the “gold standard” in studies. Three treatment arms: placebo, recommended dose of NRPT (NRPT 1X), and double dose of NRPT (NRPT 2X)|
|Results||This study shows that a repeat dose of NRPT is a safe and effective way to increase NAD+ levels sustainably.|
Result: Basis Increases NAD+ in Humans
Our first human study on Basis (NRPT) demonstrated that sustained supplementation with Basis, at the recommended dose, is a safe and effective way to increase NAD+ levels in humans — the first human study to show that for NR.
This was accomplished in a placebo-controlled trial of 120 healthy adults between the ages of 60 and 80, the first repeat-dose trial for NR as well as the first test of the combination of NR and pterostilbene in humans. The results? Participants taking the recommended dose of Basis (250 mg of NR; 50 mg of pterostilbene) saw cellular NAD+ levels increase by an average of 40 percent over baseline after 30 days, a number that was sustained at 60 days. Participants taking twice the recommended dose of Basis saw their cellular NAD+ levels increase by 90 percent over baseline after 30 days and 55 percent at 60 days. And those taking the placebo had no NAD+ increase at all. There were no serious adverse events reported in the study.
Source: Dellinger RW, Santos SR, Morris M, Evans M, Alminana D, Guarente L, Marcotulli E. Repeat dose NRPT increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. NPJ Aging Mech Dis. 2017 Nov 24;3:17. doi: 10.1038/s41514-017-0016-9.
Toxicology Study of Elysium’s Proprietary Nicotinamide Riboside (NR-E): The Safe Way to Boost NAD+
Our 2020 toxicology study published in the International Journal of Toxicology demonstrated the superior safety of the proprietary and patented nicotinamide riboside (NR-E) in Basis when compared to other NAD+ supplements. Basis is the only product that safely and sustainably increases NAD+ at the recommended dose in healthy adults.